Quality of life after bladder cancer

Quality of Life After Bladder Cancer (Q-ABC): a comparison of patient related outcomes following radical surgery and radiotherapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN38750433

Enrollment

376

Registered

2019-01-25

Start date

2018-10-13

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer Cancer

Interventions

This is a observational study collecting patient-reported quality of life questionnaires before and for 2 years following treatment for bladder cancer. It is not possible to randomise between these tr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged = 16 years, no upper age limit 2. Any patient undergoing potentially curative radical treatments for confirmed muscle invasive bladder cancer by either surgery or radiotherapy 3. Willing to provide informed consent 4. English Language competence sufficient to complete questionnaires

Exclusion criteria

Exclusion criteria: 1. Prior pelvic radiotherapy or surgery 2. Patients with bladder cancer other than transitional cell carcinoma 3. Patients who, in the judgement of the local PI, are not suitable for the study due to significant mental health disorders or cognitive impairment 4. Previous malignancy in the last 5 years except for: non-muscle invasive bladder cancer; non-melanoma skin cancer, CIS of cervix or LCIS of breast

Design outcomes

Primary

Measure	Time frame
Quality of life is measured by the EQ-5D-5L and the FACT-Bl questionnaires at baseline, 6, 12 and 24 months	—

Secondary

Measure	Time frame
1. Participant characteristics measured using the study specific CRF which includes demographic information, cancer staging, 6 items from the CTCAE V5.0 and Charlson comorbidity index at baseline 2. Fear of recurrence measured using Kornblith fear of recurrence questionnaire at baseline, 12 and 24 months 3. Survival and recurrence rates measured via follow-up CRFs at 12 and 24 months 4. Clinician graded toxicity measured by a 5-item CTCAE V5.0 and patient reported toxicity via specific items on the FACT-Bl questionnaire at 12 months 5. Costs calculated from hospital use (from CRF data about treatment and follow-up) and patient-reported costs via the UK Cancer Costs questionnaire completed at baseline and 3 monthly for the first year	—

Measure

Time frame

1. Participant characteristics measured using the study specific CRF which includes demographic information, cancer staging, 6 items from the CTCAE V5.0 and Charlson comorbidity index at baseline 2. Fear of recurrence measured using Kornblith fear of recurrence questionnaire at baseline, 12 and 24 months 3. Survival and recurrence rates measured via follow-up CRFs at 12 and 24 months 4. Clinician graded toxicity measured by a 5-item CTCAE V5.0 and patient reported toxicity via specific items on the FACT-Bl questionnaire at 12 months 5. Costs calculated from hospital use (from CRF data about treatment and follow-up) and patient-reported costs via the UK Cancer Costs questionnaire completed at baseline and 3 monthly for the first year

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026